Identification
- Summary
Tetryzoline is an alpha-adrenergic agonist used in the temporary symptomatic relief of discomfort and redness of the eyes due to minor irritations, as well as alleviate nasal congestion.
- Brand Names
- Colirio Ocusan, Visine
- Generic Name
- Tetryzoline
- DrugBank Accession Number
- DB06764
- Background
Tetryzoline, also known as tetrahydrozoline, is a derivative of imidazoline with central and peripheral alpha (α)-adrenergic properties.4 Available since the 1950s, tetryzoline is a selective α1-receptor agonist 5 that is used as an ocular and nasal decongestant. Tetryzoline is found in a wide array of over-the-counter eye drops, including the most common brand, Visine.9 Tetryzoline is also found in combination products with other lubricants and anti-irritants, such as povidone, polyethylene glycol 400, dextran, and zinc sulfate.10,11,12 It is also used in combination with other drug classes, such as antihistamines, corticosteroids, and glucocorticoids in other countries. Tetryzoline is also found in nasal spray under the trade name Tyzine, which is used for decongestion of nasal and nasopharyngeal mucosa.13
As it causes profound sedation in children and adults, tetryzoline is increasingly becoming scrutinized for possible drug overdose and toxicity from accidental ingestion.2,4 It has also been misused for non-therapeutic purposes as a causative drug for several cases of drug-facilitated sexual assault.3
- Type
- Small Molecule
- Groups
- Approved
- Structure
Structure for Tetryzoline (DB06764)
- Weight
- Average: 200.285
Monoisotopic: 200.131348523 - Chemical Formula
- C13H16N2
- Synonyms
- (RS)-2-(1,2,3,4-tetrahydronaphthalen-1-yl)-4,5-dihydro-1H-imidazole
- 2-(1,2,3,4-Tetrahydro-1-naphthyl)-2-imidazoline
- 2-Tetralin-1-yl-4,5-dihydro-1H-imidazole
- 4,5-dihydro-2-(1,2,3,4-tetrahydro-1-naphthalenyl)-1H-imidazole
- Tetrahydrozoline
- Tetrizolina
- Tetryzolin
- Tetryzolina
- Tétryzoline
- Tetryzoline
- Tetryzolinum
Pharmacology
- Indication
Tetryzoline is indicated for the temporary relief of discomfort and redness of the eye due to minor eye irritations as monotherapy 9 or in combination with other eye lubricants and anti-irritants.10,11,12
Tetryzoline is also indicated for decongestion of nasal and nasopharyngeal mucosa.13
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Used in combination to treat Active, symptomatic blepharitis Combination Product in combination with: Betamethasone (DB00443), Sulfacetamide (DB00634) •••••••••••• ••••••••• •••••••••• Used in combination to treat Blepharitis allergic Combination Product in combination with: Betamethasone (DB00443), Sulfacetamide (DB00634) •••••••••••• ••••••••• •••••••••• Used in combination to treat Blepharoconjunctivitis Combination Product in combination with: Fluorometholone (DB00324) •••••••••••• •••••••••• • ••••• Used in combination to treat Chalazion Combination Product in combination with: Fluorometholone (DB00324) •••••••••••• •••••••••• • ••••• Used in combination to treat Conjunctivitis Combination Product in combination with: Fluorometholone (DB00324) •••••••••••• •••••••••• • ••••• - Associated Therapies
- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Tetryzoline is a sympathomimetic amine and an alpha-adrenergic agonist with vasoconstricting and decongestant properties. It works by constricting the smaller arterioles of the nasal passages 13 and conjunctival blood vessels to ameliorate allergic rhinitis, nasal congestion, and ocular irritation.3 Tetryzoline is known to cross the blood-brain barrier to work on alpha-2 adrenoceptors and imidazole receptors,3 causing effects like hypotension, bradycardia, analgesia, hypothermia, sedation, and hypnosis.3
- Mechanism of action
Adrenergic receptors are G-protein-coupled receptors (GPCR) that regulate vascular tone: stimulation of alpha-1 adrenergic receptors leads to vasoconstriction. Ocular redness and nasal congestion often result from vasodilation of nasal, conjunctival, and corneal capillary blood vessels.5 Activation of alpha-1 adrenergic receptors have been therefore associated with a reduction of symptoms of ocular irritation and nasal congestion.7 Tetryzoline is a selective agonist of alpha-1 adrenergic receptors, causing vasoconstriction and alleviating ocular and nasal symptoms.5
Target Actions Organism AAlpha-1 adrenergic receptors agonistHumans UAlpha-2 adrenergic receptors agonistHumans - Absorption
When consumed orally, tetryzoline is rapidly absorbed from the gastrointestinal tract and can cross the blood-brain barrier.3 Following ocular administration of 0.05% tetryzoline, Cmax ranged from 0.068 to 0.380 ng/mL.1
- Volume of distribution
No information is available.
- Protein binding
No information is available.
- Metabolism
No information is available.
- Route of elimination
Following ocular administration of 0.05% tetryzoline, tetryzoline was detected in urine at 24 hours.1
- Half-life
Following ocular administration of 0.05% tetryzoline, the mean serum half-life was approximately 6 hours.1
- Clearance
No information is available.
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
The Lowest published toxic dose (TDLo) of tetryzoline in children following oral administration is 175 mg/kg. Oral LD50 is 785 mg/kg in rats and 345 mg/kg in mice. Intraperitoneal LD50 is 122 mg/kg in rats and 110 mg/kg in mice. Subcutaneous LD50 is 500 mg/kg in rats.15
Overdose following accidental oral ingestion in children may lead to profound sedation, possibly accompanied by profuse sweating, hypotension, and shock. In adults, hypertension, bradycardia, drowsiness, and rebound hypotension may be observed, in addition to a shock-like syndrome with hypotension and bradycardia.13 In one case, cardiovascular effects persisted for 36 hours after unintentional ingestion of tetrahydrozoline.2 Profound sedation has occurred in adults following accidental oral ingestion due to poisoning.3
Overdose should be managed with supportive treatment, with the patient kept warm. Fluid maintenance therapy may be initiated if necessary. The respiratory rate dropping to 10 or below should be responded with oxygen therapy and respiratory assistance. Blood pressure should be carefully monitored to prevent a hypotensive crisis.13 There is no known antidote to tetryzoline overdose; however, one case report illustrates the successful use of naloxone in reversing the clinical signs and symptoms of tetryzoline overdose in a child. Naloxone has been used to revere clonidine overdose. The exact mechanism of action of naloxone as an antidote is not fully understood; however, it is understood that clonidine and tetryzoline work to inhibit central sympathetic outflow by activating alpha-2 adrenoceptors and inducing endogenous opiate release, which naloxone works to antagonize.6
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
- Not Available
Interactions
- Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAcebutolol The therapeutic efficacy of Tetryzoline can be decreased when used in combination with Acebutolol. Aceclofenac The risk or severity of hypertension can be increased when Aceclofenac is combined with Tetryzoline. Acemetacin The risk or severity of hypertension can be increased when Tetryzoline is combined with Acemetacin. Acetylsalicylic acid The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Tetryzoline. Aclidinium The risk or severity of Tachycardia can be increased when Tetryzoline is combined with Aclidinium. - Food Interactions
- No interactions found.
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Product Ingredients
Ingredient UNII CAS InChI Key Tetrahydrozoline hydrochloride 0YZT43HS7D 522-48-5 BJORNXNYWNIWEY-UHFFFAOYSA-N - Generic Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Tyzine Solution 1 mg/1mL Nasal Pharma Derm, A Division Of Fougera Pharmaceuticals Inc. 1979-11-30 2017-01-31 US 
Tyzine Solution 1 mg/1mL Nasal Fougera Pharmaceuticals Inc. 1979-11-30 2013-12-31 US Tyzine Pediatric Solution 0.5 mg/1mL Nasal Fougera Pharmaceuticals Inc. 1979-11-30 2014-12-31 US Tyzine Pediatric Solution 0.5 mg/1mL Nasal Pharma Derm, A Division Of Fougera Pharmaceuticals Inc. 1979-11-30 2017-01-31 US - Over the Counter Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Assured Original Relief Eye Solution 0.5 mg/1mL Ophthalmic Greenbrier International, Inc. 2013-02-28 Not applicable US CAREALL Eyedrops Original Solution / drops .5 mg/1mL Ophthalmic New World Imports, Inc 2014-06-01 Not applicable US Circle K Eye Drops Redness Reliever Solution / drops 0.5 mg/1mL Topical Lil Drug Store Products, Inc 2016-05-04 Not applicable US CVS Redness Relief Original Solution / drops 0.5 mg/1mL Ophthalmic CVS Health 2014-03-06 Not applicable US Dg Health Original Solution 0.5 mg/1mL Ophthalmic HANLIM PHARM. CO., LTD. 2010-08-12 Not applicable US - Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image 4248 First Aid Kit Tetrahydrozoline hydrochloride (0.05 g/100mL) + Acetaminophen (325 mg/1) + Acetaminophen (110 mg/1) + Acetylsalicylic acid (162 mg/1) + Ammonia (0.045 g/0.3mL) + Bacitracin zinc (400 [iU]/1g) + Benzalkonium chloride (1.3 mg/1mL) + Benzethonium chloride (0.2 g/100g) + Benzethonium chloride (0.2 g/100g) + Benzocaine (10 g/100g) + Benzocaine (10 g/100g) + Caffeine (32.4 mg/1) + Calcium carbonate (420 mg/1) + Ethanol (0.5 mL/1mL) + Hydrocortisone acetate (1 g/100g) + Hydrocortisone acetate (1 g/100g) + Isopropyl alcohol (0.7 mL/1mL) + Lidocaine hydrochloride (20 mg/1mL) + Menthol (0.33 g/100g) + Neomycin sulfate (3.5 mg/1g) + Phenylephrine hydrochloride (5 mg/1) + Polymyxin B sulfate (5000 [iU]/1g) + Salicylamide (152 mg/1) + Water (98.6 mL/100mL) Kit Ophthalmic; Oral; Respiratory (inhalation); Topical Honeywell Safety Products USA, Inc 2018-10-18 Not applicable US 8-symptom Relief Tetrahydrozoline hydrochloride (0.05 % w/v) + Zinc sulfate (0.25 % w/v) Solution Ophthalmic TEVA Canada Limited 2016-07-22 Not applicable Canada 
Advance Relief Eye Drops Tetrahydrozoline hydrochloride (50 mg/100mL) + Dextran 70 (100 mg/100mL) + Polyethylene glycol 400 (1000 mg/100mL) + Povidone (1000 mg/100mL) Solution / drops Ophthalmic WinCo Foods, LLC 2015-01-09 Not applicable US Advanced Relief Tetrahydrozoline hydrochloride (0.5 mg/1mL) + Dextran 70 (1 mg/1mL) + Polyethylene glycol 400 (10 mg/1mL) + Povidone (10 mg/1mL) Liquid Ophthalmic Kareway Product, Inc. 2018-05-30 Not applicable US Advanced relief Tetrahydrozoline hydrochloride (0.5 mg/1mL) + Dextran 70 (1 mg/1mL) + Polyethylene glycol 400 (10 mg/1mL) + Povidone (10 mg/1mL) Liquid Ophthalmic American Sales Company 2011-09-07 Not applicable US - Unapproved/Other Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image 4248 First Aid Kit Tetrahydrozoline hydrochloride (0.05 g/100mL) + Acetaminophen (325 mg/1) + Acetaminophen (110 mg/1) + Acetylsalicylic acid (162 mg/1) + Ammonia (0.045 g/0.3mL) + Bacitracin zinc (400 [iU]/1g) + Benzalkonium chloride (1.3 mg/1mL) + Benzethonium chloride (0.2 g/100g) + Benzethonium chloride (0.2 g/100g) + Benzocaine (10 g/100g) + Benzocaine (10 g/100g) + Caffeine (32.4 mg/1) + Calcium carbonate (420 mg/1) + Ethanol (0.5 mL/1mL) + Hydrocortisone acetate (1 g/100g) + Hydrocortisone acetate (1 g/100g) + Isopropyl alcohol (0.7 mL/1mL) + Lidocaine hydrochloride (20 mg/1mL) + Menthol (0.33 g/100g) + Neomycin sulfate (3.5 mg/1g) + Phenylephrine hydrochloride (5 mg/1) + Polymyxin B sulfate (5000 [iU]/1g) + Salicylamide (152 mg/1) + Water (98.6 mL/100mL) Kit Ophthalmic; Oral; Respiratory (inhalation); Topical Honeywell Safety Products USA, Inc 2018-10-18 Not applicable US
Categories
- ATC Codes
- S01GA02 — Tetryzoline
- S01GA — Sympathomimetics used as decongestants
- S01G — DECONGESTANTS AND ANTIALLERGICS
- S01 — OPHTHALMOLOGICALS
- S — SENSORY ORGANS
- S01GA — Sympathomimetics used as decongestants
- S01G — DECONGESTANTS AND ANTIALLERGICS
- S01 — OPHTHALMOLOGICALS
- S — SENSORY ORGANS
- R01AB — Sympathomimetics, combinations excl. corticosteroids
- R01A — DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE
- R01 — NASAL PREPARATIONS
- R — RESPIRATORY SYSTEM
- Drug Categories
- Adrenergic Agonists
- Adrenergic alpha-1 Receptor Agonists
- Adrenergic alpha-Agonists
- Agents producing tachycardia
- Agents that produce hypertension
- Autonomic Agents
- Cardiovascular Agents
- Compounds used in a research, industrial, or household setting
- Decongestants and Antiallergics
- Nasal Decongestants
- Nasal Preparations
- Ophthalmic Solutions
- Ophthalmologicals
- Peripheral Nervous System Agents
- Pharmaceutical Preparations
- Pharmaceutical Solutions
- Respiratory System Agents
- Sensory Organs
- Solutions
- Sympathomimetics
- Sympathomimetics Used as Decongestants
- Sympathomimetics, Plain
- Vasoconstrictor Agents
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as tetralins. These are polycyclic aromatic compounds containing a tetralin moiety, which consists of a benzene fused to a cyclohexane.
- Kingdom
- Organic compounds
- Super Class
- Benzenoids
- Class
- Tetralins
- Sub Class
- Not Available
- Direct Parent
- Tetralins
- Alternative Parents
- Imidolactams / Imidazolines / Propargyl-type 1,3-dipolar organic compounds / Carboximidamides / Carboxamidines / Azacyclic compounds / Organopnictogen compounds / Hydrocarbon derivatives
- Substituents
- 2-imidazoline / Amidine / Aromatic heteropolycyclic compound / Azacycle / Carboximidamide / Carboxylic acid amidine / Hydrocarbon derivative / Imidolactam / Organic 1,3-dipolar compound / Organic nitrogen compound
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- carboxamidine, imidazolines (CHEBI:28674)
- Affected organisms
- Humans and other mammals
Chemical Identifiers
- UNII
- S9U025Y077
- CAS number
- 84-22-0
- InChI Key
- BYJAVTDNIXVSPW-UHFFFAOYSA-N
- InChI
- InChI=1S/C13H16N2/c1-2-6-11-10(4-1)5-3-7-12(11)13-14-8-9-15-13/h1-2,4,6,12H,3,5,7-9H2,(H,14,15)
- IUPAC Name
- 2-(1,2,3,4-tetrahydronaphthalen-1-yl)-4,5-dihydro-1H-imidazole
- SMILES
- C1CN=C(N1)C1CCCC2=CC=CC=C12
References
- General References
- Carr ME, Engebretsen KM, Ho B, Anderson CP: Tetrahydrozoline (Visine(R)) concentrations in serum and urine during therapeutic ocular dosing: a necessary first step in determining an overdose. Clin Toxicol (Phila). 2011 Nov;49(9):810-4. doi: 10.3109/15563650.2011.615064. Epub 2011 Oct 5. [Article]
- Spiller H, Griffith J: Prolonged cardiovascular effects after unintentional ingestion of tetrahydrozoline. Clin Toxicol (Phila). 2008 Feb;46(2):171-2. doi: 10.1080/15563650701258070. [Article]
- Stillwell ME, Saady JJ: Use of tetrahydrozoline for chemical submission. Forensic Sci Int. 2012 Sep 10;221(1-3):e12-6. doi: 10.1016/j.forsciint.2012.04.004. Epub 2012 May 1. [Article]
- Daggy A, Kaplan R, Roberge R, Akhtar J: Pediatric Visine (tetrahydrozoline) ingestion: case report and review of imidazoline toxicity. Vet Hum Toxicol. 2003 Aug;45(4):210-2. [Article]
- Hosten LO, Snyder C: Over-the-Counter Ocular Decongestants in the United States - Mechanisms of Action and Clinical Utility for Management of Ocular Redness. Clin Optom (Auckl). 2020 Jul 23;12:95-105. doi: 10.2147/OPTO.S259398. eCollection 2020. [Article]
- Holmes JF, Berman DA: Use of naloxone to reverse symptomatic tetrahydrozoline overdose in a child. Pediatr Emerg Care. 1999 Jun;15(3):193-4. doi: 10.1097/00006565-199906000-00008. [Article]
- Eskiizmir G, Hircin Z, Ozyurt B, Unlu H: A comparative analysis of the decongestive effect of oxymetazoline and xylometazoline in healthy subjects. Eur J Clin Pharmacol. 2011 Jan;67(1):19-23. doi: 10.1007/s00228-010-0941-z. Epub 2010 Nov 11. [Article]
- Johnson DA, Hricik JG: The pharmacology of alpha-adrenergic decongestants. Pharmacotherapy. 1993 Nov-Dec;13(6 Pt 2):110S-115S; discussion 143S-146S. [Article]
- DailyMed Label: VISINE ORIGINAL REDNESS RELIEF (tetrahydrozoline) ophthalmic solution/ drops [Link]
- DailyMed Label: CAREONE ITCHY RELIEF (tetrahydrozoline and zinc sulfate) ophthalmic solution [Link]
- DailyMed Label: CLEAR EYES TRIPLE ACTION (polyvinyl alcohol, povidone, and tetrahydrozoline) ophthalmic solution [Link]
- DailyMed Label: COLIRIO OCUSAN (tetrahydrozoline, polyethylene glycol 400, povidone, and dextran 70) ophthalmic solution [Link]
- DailyMed Label (archived): TYZINE (tetrahydrozoline) NASAL SOLUTION [Link]
- Toronto Research Chemicals: Tetrahydrozoline Safety Data Sheet [Link]
- Cayman Chemical: Tetrahydrozoline Safety Data Sheet [Link]
- External Links
- KEGG Drug
- D08578
- KEGG Compound
- C07912
- PubChem Compound
- 5419
- PubChem Substance
- 310264881
- ChemSpider
- 5226
- BindingDB
- 96559
- 37935
- ChEBI
- 28674
- ChEMBL
- CHEMBL1266
- Drugs.com
- Drugs.com Drug Page
- Wikipedia
- Tetryzoline
- FDA label
- Download (134 KB)
- MSDS
- Download (60.4 KB)
Clinical Trials
- Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
Phase Status Purpose Conditions Count 4 Completed Treatment Contact Lens Related Dry Eye 1 4 Completed Treatment Ophthalmopathy , Lacrimal System 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Kit Ophthalmic; Oral; Respiratory (inhalation); Topical Solution / drops Ophthalmic Spray Nasal Spray, suspension Nasal Solution / drops Nasal 0.1 % Solution / drops Nasal 0.05 % Solution / drops Topical 0.5 mg/1mL Solution Conjunctival; Ophthalmic 0.5 mg Solution / drops Ophthalmic 0.5 mg / mL Solution Ophthalmic 0.5 mg Suspension Ophthalmic Solution Ophthalmic 0.05 g/100mL Solution / drops Ophthalmic .5 mg/1mL Solution / drops Ophthalmic 0.5 mg/1mL Solution Ophthalmic Solution / drops Ophthalmic Liquid Topical 0.5 mg/1mL Solution / drops Ophthalmic 0.5 mg/1mg Solution / drops; suspension / drops Ophthalmic 0.5 mg/ml Solution / drops; suspension / drops Ophthalmic 0.25 mg/0.5ml Solution Ophthalmic 0.05 % w/v Solution Ophthalmic 0.05 % Solution / drops Ophthalmic .05 % Solution Ophthalmic; Topical 0.5 mg Liquid Ophthalmic 0.5 mg/1mL Suspension / drops Conjunctival Liquid Ophthalmic Solution / drops Ophthalmic 0.05 mg/1mg Solution / drops Ophthalmic 0.05 g/100mL Solution / drops Intraocular Solution / drops Ophthalmic 0.5 mg/10mg Solution / drops Ophthalmic 5 ML Solution / drops Ophthalmic 8 ML Solution / drops Conjunctival Solution Nasal 1 mg/1mL Solution Nasal 0.5 mg/1mL Solution / drops Nasal Spray Nasal Spray Nasal 0.1 % Solution Intraocular; Ophthalmic 0.5 mg Solution Conjunctival; Ophthalmic Solution / drops Ophthalmic 0.5 mg/ml Kit; solution / drops Ophthalmic Solution Ophthalmic 0.500 mg Liquid Topical Solution / drops; suspension / drops Ophthalmic 0.423 mg Solution / drops; suspension / drops Ophthalmic 0.211 mg Suspension / drops Ophthalmic Solution / drops Ophthalmic 0.05 % Solution Ophthalmic 0.5 mg/1mL Solution / drops Ophthalmic .05 mg/10mg Solution Conjunctival; Ophthalmic 0.05 mg Liquid Ophthalmic 0.05 g/100mL Solution / drops Ophthalmic 15 ml - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) >250 https://www.trc-canada.com/prod-img/MSDS/T296100MSDS.pdf - Predicted Properties
Property Value Source Water Solubility 0.239 mg/mL ALOGPS logP 3.11 ALOGPS logP 2.24 Chemaxon logS -2.9 ALOGPS pKa (Strongest Basic) 10.17 Chemaxon Physiological Charge 1 Chemaxon Hydrogen Acceptor Count 2 Chemaxon Hydrogen Donor Count 1 Chemaxon Polar Surface Area 24.39 Å2 Chemaxon Rotatable Bond Count 1 Chemaxon Refractivity 61.48 m3·mol-1 Chemaxon Polarizability 22.93 Å3 Chemaxon Number of Rings 3 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule Yes Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 141.18697 predictedDeepCCS 1.0 (2019) [M+H]+ 144.60878 predictedDeepCCS 1.0 (2019) [M+Na]+ 153.57484 predictedDeepCCS 1.0 (2019)
Targets
- Kind
- Protein group
- Organism
- Humans
- Pharmacological action
- Yes
- Actions
- Agonist
- General Function
- Protein heterodimerization activity
- Specific Function
- This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...
Components:
| Name | UniProt ID |
|---|---|
| Alpha-1A adrenergic receptor | P35348 |
| Alpha-1B adrenergic receptor | P35368 |
| Alpha-1D adrenergic receptor | P25100 |
References
- Spiller H, Griffith J: Prolonged cardiovascular effects after unintentional ingestion of tetrahydrozoline. Clin Toxicol (Phila). 2008 Feb;46(2):171-2. doi: 10.1080/15563650701258070. [Article]
- Hosten LO, Snyder C: Over-the-Counter Ocular Decongestants in the United States - Mechanisms of Action and Clinical Utility for Management of Ocular Redness. Clin Optom (Auckl). 2020 Jul 23;12:95-105. doi: 10.2147/OPTO.S259398. eCollection 2020. [Article]
- Kind
- Protein group
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Agonist
- General Function
- Thioesterase binding
- Specific Function
- Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazo...
Components:
| Name | UniProt ID |
|---|---|
| Alpha-2A adrenergic receptor | P08913 |
| Alpha-2B adrenergic receptor | P18089 |
| Alpha-2C adrenergic receptor | P18825 |
References
- Holmes JF, Berman DA: Use of naloxone to reverse symptomatic tetrahydrozoline overdose in a child. Pediatr Emerg Care. 1999 Jun;15(3):193-4. doi: 10.1097/00006565-199906000-00008. [Article]
Drug created at September 14, 2010 16:21 / Updated at February 20, 2024 23:55